Vaxart Shares Drop Despite Positive Vaccine Trial Results

Vaxart shares are trading lower after the company reported positive results from a Phase 1 trial of its second-generation oral pill norovirus vaccine, but uncertainty over partnerships and funding for future trials weighs on investor sentiment.